Compare ARK Genomic Revolution ETF (ARKG) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Manulife Financial Corporation — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while Manulife Financial Corporation trades at $41.29 (market cap $68.50B). The key difference: Manulife Financial Corporation pays a 3.23% dividend while ARK Genomic Revolution ETF pays none, and Manulife Financial Corporation is trading nearer its 52-week high, ARK Genomic Revolution ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | MFC | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $43.57 | $41.49 |
52-Week Low | $23.09 | $29.90 |
Market Cap | — | $68.50B |
Enterprise Value | — | $65.07B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Manulife Financial (MFC) trades at $41.29, down 0.48% with a bullish technical outlook. The stock shows solid fundamentals with revenue growth to $53.01B in 2025 and net income of $5.78B, though Q1 2026 earnings missed expectations. Analyst consensus is strongly bullish with 57% buy ratings, supported by positive AI developments and dividend payments.
MFC presents a compelling investment case with strong profitability metrics (ROE 13.14%) and reasonable valuation (P/E 16.89). Key risks include regulatory scrutiny in Hong Kong and wealth management outflows. The company's AI leadership and Asia growth provide upside potential, though investors should monitor execution on recent strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
